Reuters logo
BRIEF-Bayer applies for extended marketing authorisation of Regorafenib
November 7, 2016 / 7:37 AM / a year ago

BRIEF-Bayer applies for extended marketing authorisation of Regorafenib

Nov 7 (Reuters) - Bayer Ag

* Says today announced submission of applications to extend marketing authorization for its oral multi-kinase inhibitor Regorafenib in U.S., Japan and Europe, for second line treatment of patients with unresectable hepatocellular carcinoma (hcc)

* Says Regorafenib is already approved under brand name Stivarga in many countries to treat metastatic colorectal cancer and metastatic gastrointestinal stromal tumors

* Says submissions for Regorafenib are based on data from international, multicenter, placebo-controlled phase III resorce trial

* Says in U.S., Regorafenib has received fast track designation Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below